Cephalosporin

File:Cephalosporins Generation1.svg

Structure of the classical cephalosporins

The cephalosporins (sg. Template:IPAc-enTemplate:RefnTemplate:Refn) are a class of β-lactam antibiotics originally derived from the fungus Acremonium, which was previously known as Cephalosporium.<ref>Template:DorlandsDict</ref>

Together with cephamycins, they constitute a subgroup of β-lactam antibiotics called cephems. Cephalosporins were discovered in 1945, and first sold in 1964.<ref>Template:Cite book</ref>

Discovery

The aerobic mold which yielded cephalosporin C was found in the sea near a sewage outfall in Su Siccu, by Cagliari harbour in Sardinia, by the Italian pharmacologist Giuseppe Brotzu in July 1945.<ref name="HoMBRG">Template:Cite Q</ref>

Structure

Cephalosporin contains a 6-membered dihydrothiazine ring. Substitutions at position 3 generally affect pharmacology; substitutions at position 7 affect antibacterial activity, but these cases are not always true.<ref>Template:Cite web</ref>

Medical uses

Cephalosporins can be indicated for the prophylaxis and treatment of infections caused by bacteria susceptible to this particular form of antibiotic. First-generation cephalosporins are active predominantly against Gram-positive bacteria, such as Staphylococcus and Streptococcus.<ref name=":0">Template:Cite web</ref> They are therefore used mostly for skin and soft tissue infections and the prevention of hospital-acquired surgical infections.<ref name=":31424895">Template:Cite book</ref> Successive generations of cephalosporins have increased activity against Gram-negative bacteria, albeit often with reduced activity against Gram-positive organisms.Template:Cn

The antibiotic may be used for patients who are allergic to penicillin due to the different β-lactam antibiotic structure. The drug is able to be excreted in the urine.<ref name=":0" />

Side effects

Common adverse drug reactions (ADRs) (≥ 1% of patients) associated with the cephalosporin therapy include: diarrhea, nausea, rash, electrolyte disturbances, and pain and inflammation at injection site. Infrequent ADRs (0.1–1% of patients) include vomiting, headache, dizziness, oral and vaginal candidiasis, pseudomembranous colitis, superinfection, eosinophilia, nephrotoxicity, neutropenia, thrombocytopenia, and fever.Template:Cn

Allergic hypersensitivity

The commonly quoted figure of 10% of patients with allergic hypersensitivity to penicillins or carbapenems also having cross-reactivity with cephalosporins originated from a 1975 study looking at the original cephalosporins,<ref name="pmid1201975">Template:Cite journal</ref> and subsequent "safety first" policy meant this was widely quoted and assumed to apply to all members of the group.<ref name="Pegler">Template:Cite journal</ref> Hence, it was commonly stated that they are contraindicated in patients with a history of severe, immediate allergic reactions (urticaria, anaphylaxis, interstitial nephritis, etc.) to penicillins or carbapenems.<ref name="AMH2006">Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.Template:Page needed</ref>

The contraindication, however, should be viewed in the light of recent epidemiological work suggesting, for many second-generation (or later) cephalosporins, the cross-reactivity rate with penicillin is much lower, having no significantly increased risk of reactivity over the first generation based on the studies examined.<ref name="Pegler" /><ref name="pmid16451776">Template:Cite journal</ref> The British National Formulary previously issued blanket warnings of 10% cross-reactivity, but, since the September 2008 edition, suggests, in the absence of suitable alternatives, oral cefixime or cefuroxime and injectable cefotaxime, ceftazidime, and ceftriaxone can be used with caution, but the use of cefaclor, cefadroxil, cefalexin, and cefradine should be avoided.<ref>Template:Cite book</ref> A 2012 literature review similarly finds that the risk is negligible with third- and fourth-generation cephalosporins. The risk with first-generation cephalosporins having similar R1 sidechains was also found to be overestimated, with the real value closer to 1%.<ref>Template:Cite journal</ref>

MTT side chain

Template:Multiple images

Several cephalosporins are associated with hypoprothrombinemia and a disulfiram-like reaction with ethanol.<ref name="pmid3593530">Template:Cite journal</ref><ref name="pmid3350995">Template:Cite journal</ref> These include latamoxef (moxalactam), cefmenoxime, cefoperazone, cefamandole, cefmetazole, and cefotetan. This is thought to be due to the methylthiotetrazole side-chain of these cephalosporins, which blocks the enzyme vitamin K epoxide reductase (likely causing hypothrombinemia) and aldehyde dehydrogenase (causing alcohol intolerance).<ref name=Goldfrank>Template:Cite book</ref> Thus, consumption of alcohol after taking these cephalosporin orally or intravenously is contraindicated, and in severe cases can lead to death.<ref>Template:Cite journal</ref> The methylthiodioxotriazine sidechain found in ceftriaxone has a similar effect. Cephalosporins without these structural elements are believed to be safe with alcohol.<ref name="Mergenhagen2020">Template:Cite journal</ref>

Mechanism of action

Cephalosporins are bactericidal and, like other β-lactam antibiotics, disrupt the synthesis of the peptidoglycan layer forming the bacterial cell wall. The peptidoglycan layer is important for cell wall structural integrity. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by penicillin-binding proteins (PBPs). PBPs bind to the D-Ala-D-Ala at the end of muropeptides (peptidoglycan precursors) to crosslink the peptidoglycan. Beta-lactam antibiotics mimic the D-Ala-D-Ala site, thereby irreversibly inhibiting PBP crosslinking of peptidoglycan.<ref>Template:Cite journal</ref>

Resistance

Resistance to cephalosporin antibiotics can involve either reduced affinity of existing PBP components or the acquisition of a supplementary β-lactam-insensitive PBP. Compared to other β-lactam antibiotics (such as penicillins), they are less susceptible to β-lactamases. Currently, some Citrobacter freundii, Enterobacter cloacae, Neisseria gonorrhoeae, and Escherichia coli strains are resistant to cephalosporins. Some Morganella morganii, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa, Serratia marcescens and Klebsiella pneumoniae strains have also developed resistance to cephalosporins to varying degrees.<ref>Template:Cite web</ref><ref>Template:Cite journal</ref>

Classification

The first cephalosporins were designated first-generation cephalosporins, whereas, later, more extended-spectrum cephalosporins were classified as second-generation cephalosporins. Each newer generation has significantly greater Gram-negative antimicrobial properties than the preceding generation, in most cases with decreased activity against Gram-positive organisms. Fourth-generation cephalosporins, however, have true broad-spectrum activity.<ref>Template:Cite news</ref>

The classification of cephalosporins into "generations" is commonly practised, although the exact categorization is often imprecise. For example, the fourth generation of cephalosporins is not recognized as such in Japan.Template:Citation needed In Japan, cefaclor is classed as a first-generation cephalosporin, though in the United States it is a second-generation one; and cefbuperazone, cefminox, and cefotetan are classed as second-generation cephalosporins.

First generation

Cefalotin, cefazolin, cefalexin, cefapirin, cefradine, and cefadroxil are among the drugs belonging to this group.

Second generation

Cefoxitin, cefuroxime, cefaclor, cefprozil, and cefmetazole are classed as second-generation cephems.

Third generation

Ceftazidime, ceftriaxone, and cefotaxime are classed as third-generation cephalosporins. Flomoxef and latamoxef are in a new, related class called oxacephems.<ref>Template:Cite book</ref>

Fourth generation

Drugs included in this group are cefepime and cefpirome.

Further generations

Some state that cephalosporins can be divided into five or even six generations, although the usefulness of this organization system is of limited clinical relevance.<ref name="urlCase Based Pediatrics Chapter">Template:Cite web</ref>

Naming

Most first-generation cephalosporins were originally spelled "ceph-" in English-speaking countries. This continues to be the preferred spelling in the United States, Australia, and New Zealand, while European countries (including the United Kingdom) have adopted the International Nonproprietary Names, which are always spelled "cef-". Newer first-generation cephalosporins and all cephalosporins of later generations are spelled "cef-", even in the United States.Template:Citation needed

Activity

There exist bacteria which cannot be treated with cephalosporins of generations first through fourth:<ref name=":1">Template:Cite book</ref>

• Listeria spp.
• Atypicals (including Mycoplasma and Chlamydia)
• MRSA
• Enterococci

Fifth-generation cephalosporins (e.g. ceftaroline) are effective against MRSA, Listeria spp., and Enterococcus faecalis.<ref>Template:Cite journal</ref><ref name=":1" />

Overview table

rowspan=2 Template:Vert header	Name			rowspan=2 Template:Vert header	rowspan=2 Template:Vert header	Description
Common	Alternate name or spelling	Brand
(#) = noncephalosporins similar to generation #				H, human; V, veterinary; W, withdrawn; P, Pseudomonas; MR, methicillin-resistant Staphylococcus aureus; An, anaerobe
1	Cefalexin	cephalexin	Keflex	H V		Gram-positive: Activity against penicillinase-producing, methicillin-susceptible staphylococci and streptococci (though they are not the drugs of choice for such infections). No activity against methicillin-resistant staphylococci or enterococci.Template:Citation needed Gram-negative: Activity against Proteus mirabilis, some Escherichia coli, and Klebsiella pneumoniae ("PEcK"), but have no activity against Bacteroides fragilis, Pseudomonas, Acinetobacter, Enterobacter, indole-positive Proteus, or Serratia.Template:Citation needed
	Cefadroxil	cefadroxyl	Duricef	H
	Cefazolin	cephazolin	Ancef, Kefzol	H
	Cefapirin	cephapirin	Cefadryl	V
	Cefacetrile	cephacetrile
	Cefaloglycin	cephaloglycin
	Cefalonium	cephalonium
	Cefaloridine	cephaloradine
	Cefalotin	cephalothin	Keflin
	Cefatrizine
	Cefazaflur
	Cefazedone
	Cefradine	cephradine	Velosef
	Cefroxadine
	Ceftezole
2	Cefuroxime		Altacef, Zefu, Zinnat, Zinacef, Ceftin, Biofuroksym,<ref name="biofuroksym">Template:Cite web</ref> Xorimax	H		Gram-positive: Less than first-generation.Template:Citation needed Gram-negative: Greater than first-generation: HEN Haemophilus influenzae, Enterobacter aerogenes and some Neisseria + the PEcK described above.Template:Citation needed
	Cefprozil	cefproxil	Cefzil	H
	Cefaclor		Ceclor, Distaclor, Keflor, Raniclor	H
	Cefonicid		Monocid
	Cefuzonam
	Cefamandole			W
(2)	Cefoxitin		Mefoxin	H	An	Cephamycins sometimes grouped with second-generation cephalosporins
	Cefotetan		Cefotan	H	An
	Cefmetazole		Zefazone		An
	Cefminox
	Cefbuperazone
	Cefotiam		Pansporin
	Loracarbef		Lorabid			The carbacephem analog of cefaclor
3	Cefdinir		Sefdin, Zinir, Omnicef, Kefnir	H		Gram-positive: Some members of this group (in particular, those available in an oral formulation, and those with antipseudomonal activity) have decreased activity against gram-positive organisms. Activity against staphylococci and streptococci is less with the third-generation compounds than with the first- and second-generation compounds.<ref>Template:Cite book</ref> Gram-negative: Third-generation cephalosporins have a broad spectrum of activity and further increased activity against gram-negative organisms. They may be particularly useful in treating hospital-acquired infections, although increasing levels of extended-spectrum beta-lactamases are reducing the clinical utility of this class of antibiotics. They are also able to penetrate the central nervous system, making them useful against meningitis caused by pneumococci, meningococci, H. influenzae, and susceptible E. coli, Klebsiella, and penicillin-resistant N. gonorrhoeae. Since August 2012, the third-generation cephalosporin, ceftriaxone, is the only recommended treatment for gonorrhea in the United States (in addition to azithromycin or doxycycline for concurrent Chlamydia treatment). Cefixime is no longer recommended as a first-line treatment due to evidence of decreasing susceptibility.<ref>Template:Cite journal</ref>
	Ceftriaxone		Rocephin	H
	Ceftazidime		Meezat, Fortum, Fortaz	H	P
	Cefixime		Fixx, Zifi, Suprax	H
	Cefpodoxime		Vantin, PECEF, Simplicef	H V
	Ceftiofur		Naxcel, Excenel	H V
	Cefotaxime		Claforan	H
	Ceftizoxime		Cefizox	H
	Cefditoren		Zostom-O	H
	Ceftibuten		Cedax	H
	Cefovecin		Convenia	V
	Cefdaloxime
	Cefcapene
	Cefetamet
	Cefmenoxime
	Cefodizime
	Cefpimizole
	Cefteram
	Ceftiolene
	Cefoperazone		Cefobid	W<ref name="StatPearls">Template:Cite book</ref>	P
(3)	Latamoxef	moxalactam		W<ref name="StatPearls" />		An oxacephem sometimes grouped with third-generation cephalosporins
4	Cefepime		Maxipime	H	P	Gram-positive: They are extended-spectrum agents with similar activity against Gram-positive organisms as first-generation cephalosporins.Template:Citation needed Gram-negative: Fourth-generation cephalosporins are zwitterions that can penetrate the outer membrane of Gram-negative bacteria.<ref name="SweetGibbs2009">Template:Cite book</ref> They also have a greater resistance to β-lactamases than the third-generation cephalosporins. Many can cross the blood–brain barrier and are effective in meningitis. They are also used against Pseudomonas aeruginosa.Template:Citation needed Cefiderocol has been called a fourth-generation cephalosporin by only one source as of November 2019.<ref>Template:Cite web</ref>
	Cefiderocol		Fetroja	H
	Cefquinome			V
	Cefclidine
	Cefluprenam
	Cefoselis
	Cefozopran
	Cefpirome		Cefrom
(4)	Flomoxef					An oxacephem sometimes grouped with fourth-generation cephalosporins
5	Ceftaroline			H	MR	Ceftobiprole has been described as "fifth-generation" cephalosporin,<ref name="pmid18225983">Template:Cite journal</ref><ref name="pmid17613382">Template:Cite journal</ref> though acceptance for this terminology is not universal. Ceftobiprole has anti-pseudomonal activity and appears to be less susceptible to development of resistance. Ceftaroline has also been described as "fifth-generation" cephalosporin, but does not have the activity against Pseudomonas aeruginosa or vancomycin-resistant enterococci that ceftobiprole has.<ref name="pmid20001879">Template:Cite journal</ref> Ceftolozane is an option for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. It is combined with the β-lactamase inhibitor tazobactam, as multi-drug resistant bacterial infections will generally show resistance to all β-lactam antibiotics unless this enzyme is inhibited.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>
	Ceftolozane		Zerbaxa	H
	Ceftobiprole				MR
?	Cefaloram					These cephems have progressed far enough to be named, but have not been assigned to a particular generation. Nitrocefin is a chromogenic cephalosporin substrate, and is used for detection of β-lactamases.Template:Citation needed
	Cefaparole
	Cefcanel
	Cefedrolor
	Cefempidone
	Cefetrizole
	Cefivitril
	Cefmatilen
	Cefmepidium
	Cefoxazole
	Cefrotil
	Cefsumide
	Ceftioxide
	Cefuracetime
	Nitrocefin

History

Template:See also Cephalosporin compounds were first isolated from cultures of Acremonium strictum from a sewer in Sardinia in 1948 by Italian scientist Giuseppe Brotzu.<ref>Template:Cite bookTemplate:Page needed</ref> He noticed these cultures produced substances that were effective against Salmonella typhi, the cause of typhoid fever, which had β-lactamase. Guy Newton and Edward Abraham at the Sir William Dunn School of Pathology at the University of Oxford isolated cephalosporin C. The cephalosporin nucleus, 7-aminocephalosporanic acid (7-ACA), was derived from cephalosporin C and proved to be analogous to the penicillin nucleus 6-aminopenicillanic acid (6-APA), but it was not sufficiently potent for clinical use. Modification of the 7-ACA side chains resulted in the development of useful antibiotic agents, and the first agent, cefalotin (cephalothin), was launched by Eli Lilly and Company in 1964.Template:Citation needed

External links

• Cephalosporins